Treatment Approach to Patients With Severe Insulin Resistance

Timothy J Church, Stuart T Haines, Timothy J Church, Stuart T Haines

Abstract

In Brief Patients with severe insulin resistance require >2 units/kg of body weight or 200 units/day of insulin. Yet, many patients do not achieve glycemic targets despite using very high doses of insulin. Insulin can cause weight gain, which further contributes to worsening insulin resistance. This article describes the pharmacological options for managing patients with severe insulin resistance, including the use of U-500 insulin and newer agents in combination with insulin.

Figures

FIGURE 1.
FIGURE 1.
U-500 regular insulin initial dosing recommendations (6,55).

References

    1. Crasto W, Hackett JE, Nayyar V, et al. . Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgrad Med J 2009;85:219–222
    1. American Diabetes Association Consensus development conference on insulin resistance. Diabetes Care 1997;21:310–314
    1. Ovalle F. Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract 2010;90:231–242
    1. Galloway JA, Root MA, Bergstrom R, et al. . Clinical pharmacologic studies with human insulin (recombinant DNA). Diabetes Care 1982;5(Suppl. 2):12–22
    1. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations, part 2: drug-induced hyperglycemia. Diabetes Spectrum 2011;24:234–238
    1. Lane WS, Cochran EK, Jackson JA, et al. . High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15:71–79
    1. Binder C. Absorption of injected insulin: a clinical-pharmacological study. Acta Pharmacol Toxicol 1969;27(Suppl. 2):1–84
    1. Humalog Kwikpen (insulin lispro) injection [package insert]. Indianapolis, IN, Lilly USA, 2015
    1. Toujeo (insulin glargine) U-300 injection [package insert]. Bridgewater, NJ, Sanofi-Aventis US, 2015
    1. Davidson MB, Navar MD, Echeverry D, et al. . U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin resistant type 2 diabetic patients. Diabetes Care 2010;33:281–230
    1. Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care 2006;29:2175–2176
    1. Nayyar V, Lawrence I, Kong MF, et al. . Long-term follow-up of patients on U-500 insulin: a case-series. Pract Diabetes Int 2010;27:194–197
    1. Dailey AM, Williams S, Taneja D, et al. . Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract 2010;88:259–264
    1. Garg R, Lawrence IG, Akinsola MO, et al. . Improved glycemic control in severely insulin resistant, insulin treated diabetic patients with U-500 Human Actrapid over two year follow-up. (Abstract). Diabetologia 2004;47(Suppl. 1):A58
    1. Boldo A, Comi RJ. Clinical experience with U500 insulin: risks and benefits. Endocr Pract 2012;18:56–61
    1. Quinn SL, Lansang MC, Mina D. Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus. Pharmacotherapy 2011;31:695–702
    1. Ziesmer AE, Kelly KC, Guerra PA, et al. . U-500 regular insuline use in insulin-resistant type 2 diabetic verteran patients. Endocr Pract 2012;18:34–38
    1. Granata JA, Nawarskas AD, Resch ND, et al. . Evalutating the effect of U-500 insulin therapy on glycemic control in verterans with type 2 diabetes. Clinical Diabetes 2015;33:14–19
    1. Reutrakul S, Weoblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol 2012;6:412–420
    1. Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract 2006;12:251–256
    1. Humulin R. U-500 concentrated insulin [package insert]. Indianapolis, IN, Eli Lilly and Co., 1996
    1. American Diabetes Association Standards of medical care in diabetes—2015. Diabetes Care 2015;38(Suppl. 1):S1–S94
    1. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 2011;13:592–595
    1. Lane W, Weinrib S, Rappaport J, et al. . The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes Metab 2014;16:827–832
    1. Wulffele M, Kooy A, Lehert P, et al. . Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002;25:2133–2140
    1. Ponssen HH, Elte JWF, Lehert P, et al. . Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther 2000;22:709–718
    1. Blonde L, Dailey GE, Jabbour SA, et al. . Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin 2004;20:565–572
    1. Lipska KJ. Bailer CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431–1437
    1. Salpeter S, Greyber E, Pasternak G, et al. . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;14:CD002967
    1. KDIGO KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150
    1. America Geriatrics Society Expert Panel Guidelines abstracted from the American Geriatrics Society guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geritr Soc 2013;61:2020–2026
    1. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34(Suppl. 2):279–284
    1. Eng C, Kramer CK, Zinman B, et al. . Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228–2234
    1. Distiller LA, Nortje H, Wellmann H, et al. . A 24-week prospective, randomized, open label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance plus the addition of exenatide on the efficacy of U-500 regular insulin plus metformin. Endocr Pract 2014;20:1143–1150
    1. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015;6:19–28
    1. Valentine V. The role of the kidney and sodium-glucose cotransporter 2 inhibition in diabetes management. Clinical Diabetes 2012;30:151–155
    1. Rosenstock J, Jelaska A, Frappin G, et al. . Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815–1823
    1. Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 2014;15:2565–2685
    1. Charbonnel B, Schhweizer A, Dejager S. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract 1995;41:93–107
    1. Rosenstock J, Rendell MS, Gross JL, et al. . Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11:1145–1152
    1. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. . Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167–177
    1. McGill JB, Sloan L, Newman J, et al. . Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36:237–244
    1. Barnett AH, Charbonnel B, Li J, et al. . Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig 2015;35:179–185
    1. Symlin (pramlintide) injection [package insert]. Wilmington, DE, AstraZeneca, 2014
    1. Hollander PA, Levy P, Fineman MS, et al. . Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26:784–790
    1. Ratner RE, Want LL, Fineman MS, et al. . Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002;4:51–61
    1. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled withbes combination therapy. Diabetes Obes Metab 2007;9:512–520
    1. Kelley DE, Bidot P, Freedman Z, et al. . Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2056–2061
    1. Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care 2011;34(Suppl. 2):S244–S250
    1. Goldberg RB, Fonesca VA, Truitt KE, et al. . Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531–1540
    1. Cycloset (bromocriptine) oral [package insert]. San Diego, CA, Santarus, 2010
    1. Holman RR, Paul SK, Bethel MA, et al. . 10-year follow-up of intensive glucose control in type 2 diabetes. N Eng J Med 2008;359:1577–1589
    1. Apovian CM, Aronne LJ, Bessesen DH, et al. . Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342–362
    1. RedBook Online. Ann Arbor MI, Truven Health Analytics, 2015. Available by subscription only from . Accessed 13 March 2015
    1. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005;28:1240–1244

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir